We have a number of laser-focused, high-impact programs that allow us to educate stakeholders about the barriers, amplify solutions that could pave the way to progress, and create opportunities for key leaders to come together and get things done.
We work alongside patient advocates, researchers, investors, and policymakers across all sectors of the medical research and development system to achieve the following strategic goals through our programs.
Stimulate Innovative Collaborations across all sectors - academia, government, industry, investors, and nonprofits.
Partnering for Cures. Brings together annually more than 1,000 leaders from across sectors in medical research to accelerate innovative partnerships and to forge solutions. In its fifth year, it has become medical research’s most forward-thinking, outcomes-oriented, and patient-focused event.
(TRAIN) The Research Acceleration and Innovation Network and TRAIN Central Station. Connects outcomes-driven research foundations around hot-button issues and amplifies their best practices to the rest of the community. These groups, known as venture philanthropies, are often created by patients and families frustrated by the slow pace of the traditional research system. Their urgency for results is transforming the medical research enterprise. TRAIN Central Station, an online platform for real-time sharing of tools and lessons, keeps TRAIN groups and other stakeholders abreast of the progress they are making and highlights opportunities to work together.
Consortia-pedia. Articulates models for building and success factors for implementing and sustaining multi-stakeholder consortia in medical R&D. This effort also features the consortia-pedia, an inventory of consortia efforts, that allows collaborators to more easily find and learn from one another. By harnessing the experience and lessons of pioneering bioscience collaborations already underway, future efforts can be more effective and streamlined.
Academic Collaborations. Spurs greater understanding and broader awareness of new academic models and partnerships and their role in the therapy development process.
Intellectual Property (IP) Intersection. Provides a set of guiding principles and points to consider in developing IP agreements.
- This online resource features tools to help new players navigate the IP landscape and dissect evolving paradigms, relationships, and funding structures.
Increase patient engagement in research and optimize use of patient data.
Patients Helping Doctors (PHD). Spotlights emerging models that organize patients, their data, and specimens, to better support R&D.
- The Greatest HITS (Greatest Health Information Technology Stories) program features examples of innovations in collecting, aggregating, and analyzing patient data and applying them to medical research.
- The Clinical Trials Data Transparency effort informs the discussion about the degree to which clinical trial data are publicly accessible to researchers and care providers. It helps ensure data-sharing practices are reflective and inclusive of all stakeholder interests, particularly those of patients.
Time Equals Lives Campaign. Provides a social media platform to collect and share compelling stories about why we must invest in medical research. Through a collection of powerful personal stories from patients, researchers, and advocates, it makes a strong case for why research matters and creates a public policy imperative to make research a national priority.
Improve research process and policy to support efficient development and approval of new therapies.
NIH & FDA Advocacy. Focuses on strategic advocacy tactics to inform policy decision makers and advocates about the vital roles government agencies like the National Institutes of Health (NIH) and Food and Drug Administration (FDA) play in getting new medicines from discovery to patients. Proper funding for these agencies is critical to achieving a more efficient and productive medical research system.
Benefit-Risk Framework. Provides guidance and a framework for patient communities to collect and analyze data and develop tools to capture benefit-risk information that will be helpful to FDA reviewers. It brings together existing tools and processes for data collection and analysis and creates a platform for sharing these resources with the broader patient community.
Care Innovation. Explores avenues for payers, FDA, patient organizations, and other stakeholders to intersect early in the research process, and examines trends in reimbursement policies of innovative therapies.
Facilitate greater access and more strategic allocation of capital to support results-driven medical research.
Philanthropy Advisory Service. Provides comprehensive and science-based tools to allow philanthropists to critically assess giving opportunities in nonprofit medical research to best direct investments to high-impact organizations.
Fixes in Financing. Explores and evaluates new models to finance translational research in order to achieve greater awareness of emerging innovations and experimentation in developing new novel models and increase private investment in early-stage biomedical research.